online). Compared with that in Caucasian cohorts, the mutation rate of BRAF is low in Chinese melanoma cases; a similar result was obtained by Qi et al. (2011) . With regard to the mutation rates of KIT in northern and southern Chinese patients, the latter showed a lower frequency (Kong et al., 2011) . One possible explanation for differences between our results and those of Kong et al. is that some hotspots covered in the study by Kong et al. are not included in mutation profiles of the MassARRAY System.
EGFR mutation was documented in 1 of 238 melanomas in the COSMIC (the Catalog of Somatic Mutations in Cancer) database. In the present study, EGFR mutations were observed in 3 of 28 (10.7%) acral melanomas (EGFR T790M and EGFR L861Q) and in 1 of 28 (3.6%) mucosal melanomas (EGFR E749-A750del). Interestingly, three of four cases with EGFR mutations were concurrent with other mutations (Table 1) , and these relationships would complicate the response of melanomas to EGFR inhibitors (Patel et al., 2011) .
Currently, it remains unclear how cooccurring mutations arise. In many cases, mutations in a single gene in one signaling pathway cannot significantly affect cellular signaling, and accumulated mutations in the activated signaling pathway tend to amplify the effects of cancer gene mutations and have significant influences on the dysfunction of the signaling pathway. These co-occurring mutations may therefore function synergistically in tumor formation and development (Cui, 2010) .
Although most patients who undergo targeted therapy are diagnosed at an advanced stage with metastases, the mutation status is routinely analyzed using primary tumors. Given the heterogeneity of malignant carcinoma at the molecular level, we examined the discrepancy in oncogenic mutations between primary tumors and the corresponding lymph node metastases. Of 28 patients, 17 (60.7%) with wild-type status in the primary tumor lacked a mutation in the corresponding lymph node. In all, 11 of 28 patients (39.3%) had mutations in the primary tumors and 8 (28.6%) had mutations in the metastatic lymph nodes, respectively. Of those 11 patients with mutations in the primary tumor, 5 patients (45.5%) had concordant mutations in the metastatic lymph nodes, and 3 patients (27.3%) had mutations only in the primary tumors. Furthermore, two patients (18.2%) had co-occurring mutations in the primary tumors and only a single mutation in the metastatic lymph nodes. One patient (9.1%) presented with two completely different mutations between the primary tumor and the metastatic lymph node (Table 2) .
Our results demonstrated that melanoma cells that metastasize to the lymph nodes do not always carry the same mutations as the primary tumors. However, the molecular basis of metastasis is still unclear. Two major models of tumor progression and metastasis, the linear progression model and the parallel progression model, are applicable in melanoma progression. The concordant mutation status between primary tumors and metastatic lymph nodes suggests that, in some melanoma cases, genetic mutations occur before the tumor metastasizes, and these mutations are then preserved through the subsequent stages of tumor development, and no selection occurs during metastasis. Such observations have also been reported for lung cancer cases (Chang et al., 2011) . This is in agreement with the concept of the linear progression model (Klein, 2009 ). The discordant mutation status between primary tumors and metastatic lymph nodes suggests that metastasis is a relatively early event in tumor progression, and the primary and metastatic tumors evolve independently according to the different environments, as reported by Schmidt-Kittler et al. (2003) in breast cancer cases. This discordance is consistent with the parallel progression model (Klein, 2009; Chang et al., 2011; Han et al., 2011) . However, because the specimens contain a mixture of tumor and normal cells, it cannot be ruled out that the mutations that we observed in the primary tumors are already present in a minor fraction of tumor cells in the metastatic lymph nodes that we could not detect in the analysis. The mutation prevalence in melanoma susceptibility genes may vary within each specific geographical area (Casula et al., 2009) . In this study, we demonstrated that there is a tendency for oncogene mutations in southern Chinese melanoma cases to occur infrequently, but with BRAF, NRAS, KIT, and EGFR mutations being the most frequent. The observed discordance in the mutation status between the primary melanomas and the metastatic lymph nodes implies that caution must be taken when therapeutic decisions are based solely on the biological properties of the primary tumor.
